Trial · NCT01262014
Clinical Trial Investigating Pazopanib in Patients With Platinum-resistant Advanced Ovarian Cancer
NCT01262014, Phase 2, Completed, Grupo Español de Investigación en Cáncer de Ovario
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Trial Investigating Pazopanib in Patients With Platinum-resistant Advanced Ovarian Cancer. Trials, record NCT01262014. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01262014
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Trial Investigating Pazopanib in Patients With Platinum-resistant Advanced Ovarian Cancer
- NCT number
- NCT01262014
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 28 participants, actual
- Lead sponsor
- Grupo Español de Investigación en Cáncer de Ovario
- Conditions
- Platinum-resistant Advanced Ovarian Cancer
- Interventions
- Pazopanib
- First posted
- 2010-12-17
- Last updated
- 2016-08-11
- Other registries' IDs
- eudract:2010-020439-38
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The primary efficacy endpoint for this study is Clinical Benefit Rate | average 30 months | Clinical Benefit Rate defined as the percentage of patients with Complete Response plus Partial Response plus Stable Disease ≥ 8 weeks by RECIST v1.1 |
| Secondary | Progression Free Survival (PFS) | average 30 months | Progression Free Survival (PFS) is defined as the time from the day of starting treatment to the first evidence of progression as defined by RECIST guidelines (v1.1) or death from any cause. If the patient does not have a documented date of progression or death, then PFS will be censored at the date of last adequate assessment. |
| Secondary | Biological Response by CA-125 (GCIG Criteria) | average 30 months | CA-125 Testing: at pretreatment visit and during the treatment period and then every 3 months after discontinuation of treatment due to any reason (toxicity or patient will) until disease progression. |
| Secondary | Overall Survival (OS) | Average 3 years | Overall Survival (OS) is defined as the time from first day of therapy to the date of death from any cause. For a patient who is alive at the time of the statistical analysis, the patient will be considered censored at the last date of known contact. |
| Secondary | Biological progression-free interval (PFIBIO) | average 30 months | CA-125 Testing: at pretreatment visit and during the treatment period and then every 3 months after discontinuation of treatment due to any reason (toxicity or patient will) until disease progression. PFIBIO will be assessed according to the GCIG criteria |
| Secondary | Quality of Life and symptom control | average 5 years | Quality of Life and symptom control will be assessed using EORTC QLQ-C30, QLQOV28, FACT/NCCN Ovarian Symptom Index (FOSI) |
| Secondary | The safety and tolerability of study drug | Average 5 years | The safety and tolerability of study drugs are determined type, incidence, severity, timing, seriousness, and relatedness; of reported AEs, physical examinations, and laboratory tests. Toxicity will be graded and tabulated by the NCI-CTCAE v 3.0. |
| Secondary | Descriptive pharmacodynamic profile | 30 months | * the association between tumor PDGFRα expression (assessed by immunohistochemistry) and clinical outcomes (PFS, ORR, etc) * the relationship between serum VEGF/PDGF levels and clinical outcomes. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01262014
GET https://conductscience.org/api/trials/v1/NCT01262014/registered